ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more
ABVC Biopharma Inc (ABVC) - Net Assets
Latest net assets as of December 2025: $13.30 Million USD
Based on the latest financial reports, ABVC Biopharma Inc (ABVC) has net assets worth $13.30 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.06 Million) and total liabilities ($7.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.30 Million |
| % of Total Assets | 63.13% |
| Annual Growth Rate | 36.71% |
| 5-Year Change | 49.91% |
| 10-Year Change | N/A |
| Growth Volatility | 5866.87 |
ABVC Biopharma Inc - Net Assets Trend (2002–2025)
This chart illustrates how ABVC Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ABVC Biopharma Inc (2002–2025)
The table below shows the annual net assets of ABVC Biopharma Inc from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $13.30 Million | +1736.77% |
| 2024-12-31 | $723.96K | -42.24% |
| 2023-12-31 | $1.25 Million | -72.69% |
| 2022-12-31 | $4.59 Million | -48.25% |
| 2021-12-31 | $8.87 Million | +52.35% |
| 2020-12-31 | $5.82 Million | +4764.77% |
| 2019-12-31 | $-124.82K | +97.83% |
| 2018-12-31 | $-5.75 Million | -333.70% |
| 2017-12-31 | $2.46 Million | +137.74% |
| 2016-12-31 | $-6.52 Million | -22520.58% |
| 2015-12-31 | $29.08K | -4.86% |
| 2014-12-31 | $30.56K | +102.09% |
| 2011-12-31 | $-1.46 Million | +51.11% |
| 2010-12-31 | $-2.99 Million | -48.90% |
| 2009-12-31 | $-2.01 Million | -62.17% |
| 2008-12-31 | $-1.24 Million | -527.10% |
| 2007-12-31 | $290.29K | +722.93% |
| 2006-12-31 | $35.27K | -41.86% |
| 2005-12-31 | $60.67K | -30.53% |
| 2004-12-31 | $87.34K | +9.18% |
| 2003-12-31 | $80.00K | +700.00% |
| 2002-12-31 | $10.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ABVC Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7683836100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $25.05K | 0.23% |
| Other Comprehensive Income | $487.60K | 4.39% |
| Other Components | $87.46 Million | 787.06% |
| Total Equity | $11.11 Million | 100.00% |
ABVC Biopharma Inc Competitors by Market Cap
The table below lists competitors of ABVC Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adyton Resources Corporation
PINK:ADYRF
|
$26.44 Million |
|
Arena Group Holdings Inc
NYSE MKT:AREN
|
$26.45 Million |
|
Crown Confectionery Co Ltd
KO:264900
|
$26.48 Million |
|
Ulusoy Elektrik Imalat
IS:ULUSE
|
$26.48 Million |
|
Yuyu Pharma Inc
KO:000227
|
$26.44 Million |
|
Malaysian Bulk Carriers Bhd
KLSE:5077
|
$26.44 Million |
|
CIFI Holdings (Group) Co. Ltd
F:6CI
|
$26.44 Million |
|
Ebebek Magazacilik Anonim Sirketi
IS:EBEBK
|
$26.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABVC Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,226,140 to 11,111,861, a change of 9,885,721 (806.2%).
- Net loss of 7,908,554 reduced equity.
- Other comprehensive income increased equity by 10,897.
- Other factors increased equity by 17,783,378.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.91 Million | -71.17% |
| Other Comprehensive Income | $10.90K | +0.1% |
| Other Changes | $17.78 Million | +160.04% |
| Total Change | $- | 806.25% |
Book Value vs Market Value Analysis
This analysis compares ABVC Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.03x to 2.78x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $44.64 | $1.33 | x |
| 2003-12-31 | $357.14 | $1.33 | x |
| 2004-12-31 | $2360.65 | $1.33 | x |
| 2005-12-31 | $1639.84 | $1.33 | x |
| 2006-12-31 | $953.38 | $1.33 | x |
| 2007-12-31 | $7845.59 | $1.33 | x |
| 2008-12-31 | $-10079.76 | $1.33 | x |
| 2009-12-31 | $-91393.50 | $1.33 | x |
| 2010-12-31 | $-130335.96 | $1.33 | x |
| 2011-12-31 | $-29870.88 | $1.33 | x |
| 2014-12-31 | $160.86 | $1.33 | x |
| 2015-12-31 | $0.01 | $1.33 | x |
| 2016-12-31 | $-5.57 | $1.33 | x |
| 2017-12-31 | $1.40 | $1.33 | x |
| 2018-12-31 | $-4.84 | $1.33 | x |
| 2019-12-31 | $-0.09 | $1.33 | x |
| 2020-12-31 | $3.35 | $1.33 | x |
| 2021-12-31 | $3.53 | $1.33 | x |
| 2022-12-31 | $1.41 | $1.33 | x |
| 2023-12-31 | $0.36 | $1.33 | x |
| 2024-12-31 | $0.11 | $1.33 | x |
| 2025-12-31 | $0.48 | $1.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABVC Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -993.60%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.90x
- Recent ROE (-71.17%) is above the historical average (-183.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -200.00% | -200.00% | 0.25x | 4.00x | $-21.00K |
| 2003 | -31.70% | -185.54% | 0.12x | 1.38x | $-33.36K |
| 2004 | 2.91% | 4.42% | 0.64x | 1.03x | $-6.20K |
| 2005 | -43.96% | -156.11% | 0.27x | 1.04x | $-32.74K |
| 2006 | -72.00% | -60.71% | 0.47x | 2.50x | $-28.93K |
| 2007 | -1602.16% | -11161.73% | 0.03x | 4.15x | $-4.68 Million |
| 2008 | 0.00% | -26981.99% | 0.02x | 0.00x | $-6.65 Million |
| 2009 | 0.00% | 0.00% | -0.52x | 0.00x | $-4.98 Million |
| 2010 | 0.00% | -12793.14% | 0.05x | 0.00x | $-1.60 Million |
| 2011 | 0.00% | -38202.23% | 0.01x | 0.00x | $-1.07 Million |
| 2014 | -78.85% | -309.49% | 0.12x | 2.11x | $-27.16K |
| 2015 | -111.02% | -960.74% | 0.05x | 2.35x | $-35.19K |
| 2016 | 0.00% | -34399184.38% | 0.00x | 0.00x | $-10.36 Million |
| 2017 | -256.61% | -132755.32% | 0.00x | 3.99x | $-4.41 Million |
| 2018 | 0.00% | -80152.08% | 0.07x | 0.00x | $-5.00 Million |
| 2019 | 0.00% | -518.98% | 0.10x | 0.00x | $-3.63 Million |
| 2020 | -148.38% | -2026.97% | 0.03x | 2.24x | $-10.45 Million |
| 2021 | -145.18% | -3608.47% | 0.03x | 1.55x | $-13.72 Million |
| 2022 | -368.81% | -1693.50% | 0.09x | 2.46x | $-16.87 Million |
| 2023 | -501.13% | -5109.26% | 0.02x | 5.01x | $-7.94 Million |
| 2024 | -399.86% | -962.12% | 0.07x | 6.15x | $-5.03 Million |
| 2025 | -71.17% | -993.60% | 0.04x | 1.90x | $-9.02 Million |
Industry Comparison
This section compares ABVC Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -200.00% | 0.58x | $26.44 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |